Clinical Data ACC 2026: dulaglutide promotes coronary plaque stabilisation in patients with T2D Pharmaceutical TechnologyData presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes.Clinical DataCardiovascularRead full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaceutical Technology Data presented at ACC 2026 suggests that dulaglutide may be stabilising coronary plaques from the inside out, as well as managing diabetes. Clinical DataCardiovascularRead full story Post navigation Previous: Biopharma M&A Heats Up, Rare Diseases Win Three Approvals, Wave CrashesNext: Viridian reports positive results from elegrobart phase 3 trial Related Stories Clinical Data BridgeBio stands up to Pfizer in ATTR-CM as late-stage data hint at better survival pharminent May 12, 2026 Clinical Data Novo says high-dose Wegovy can cause 28% weight loss pharminent May 12, 2026 Clinical Data Pulsesight reports positive phase 1 data for PST611 in dry AMD pharminent May 11, 2026
